OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment
Ruyin Chen, Qiong Li, Shuaishuai Xu, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 34
Ruyin Chen, Qiong Li, Shuaishuai Xu, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 34
Showing 1-25 of 34 citing articles:
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Yang Yang, Shuo Li, Yujiao Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 141
Yang Yang, Shuo Li, Yujiao Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 141
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 23
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 23
A comprehensive and systematic review on potential anticancer activities of eugenol: From pre-clinical evidence to molecular mechanisms of action
Syeda Nurunnesa Begum, Anindya Sundar Ray, Chowdhury Habibur Rahaman
Phytomedicine (2022) Vol. 107, pp. 154456-154456
Closed Access | Times Cited: 41
Syeda Nurunnesa Begum, Anindya Sundar Ray, Chowdhury Habibur Rahaman
Phytomedicine (2022) Vol. 107, pp. 154456-154456
Closed Access | Times Cited: 41
Regulation and targeting of SREBP-1 in hepatocellular carcinoma
Fengting Su, Andreas Koeberle
Cancer and Metastasis Reviews (2023) Vol. 43, Iss. 2, pp. 673-708
Open Access | Times Cited: 33
Fengting Su, Andreas Koeberle
Cancer and Metastasis Reviews (2023) Vol. 43, Iss. 2, pp. 673-708
Open Access | Times Cited: 33
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Y. Qin, Shisong Han, Yahan Yu, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1808-1831
Closed Access | Times Cited: 11
Y. Qin, Shisong Han, Yahan Yu, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1808-1831
Closed Access | Times Cited: 11
Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC)
Jingquan Huang, Qiulin Wu, David A. Geller, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 21
Jingquan Huang, Qiulin Wu, David A. Geller, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 21
Apoptosis‐Sensitizing Tumor Nanomedicine by Regulating Pyroptosis‐Associated Inflammatory Cell Death
Fangxue Du, Hongxin Zhao, Yangmeihui Song, et al.
Advanced Functional Materials (2024) Vol. 34, Iss. 44
Closed Access | Times Cited: 7
Fangxue Du, Hongxin Zhao, Yangmeihui Song, et al.
Advanced Functional Materials (2024) Vol. 34, Iss. 44
Closed Access | Times Cited: 7
Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects
Xuan-Yu Gu, Jinlong Huo, Yu Zhiyong, et al.
ONCOLOGIE (2024) Vol. 26, Iss. 1, pp. 9-25
Open Access | Times Cited: 6
Xuan-Yu Gu, Jinlong Huo, Yu Zhiyong, et al.
ONCOLOGIE (2024) Vol. 26, Iss. 1, pp. 9-25
Open Access | Times Cited: 6
Inulin‐Based Nanoparticle Modulates Gut Microbiota and Immune Microenvironment for Improving Colorectal Cancer Therapy
Runqi Zhu, Wenhui Yuan, Anqi Xia, et al.
Advanced Functional Materials (2024)
Closed Access | Times Cited: 6
Runqi Zhu, Wenhui Yuan, Anqi Xia, et al.
Advanced Functional Materials (2024)
Closed Access | Times Cited: 6
Prediction of cancer nanomedicines self-assembled from meta-synergistic drug pairs
Dana Meron Azagury, Ben Friedmann Gluck, Yuval Harris, et al.
Journal of Controlled Release (2023) Vol. 360, pp. 418-432
Closed Access | Times Cited: 14
Dana Meron Azagury, Ben Friedmann Gluck, Yuval Harris, et al.
Journal of Controlled Release (2023) Vol. 360, pp. 418-432
Closed Access | Times Cited: 14
The Role of Type 2 Diabetes Mellitus–Related Risk Factors and Drugs in Hepatocellular Carcinoma
Yuhua Mai, Liheng Meng, Ganlu Deng, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 159-171
Open Access | Times Cited: 5
Yuhua Mai, Liheng Meng, Ganlu Deng, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 159-171
Open Access | Times Cited: 5
Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review)
Ruijia Liu, Xudong Yu, Shao-Shuai Yan, et al.
International Journal of Oncology (2024) Vol. 64, Iss. 6
Open Access | Times Cited: 5
Ruijia Liu, Xudong Yu, Shao-Shuai Yan, et al.
International Journal of Oncology (2024) Vol. 64, Iss. 6
Open Access | Times Cited: 5
The multifaceted roles of macrophages in the transition from hepatitis to hepatocellular carcinoma: From mechanisms to therapeutic strategies
Shuairan Zhang, Dong Hang, Xiuli Jin, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025) Vol. 1871, Iss. 3, pp. 167676-167676
Closed Access
Shuairan Zhang, Dong Hang, Xiuli Jin, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025) Vol. 1871, Iss. 3, pp. 167676-167676
Closed Access
The glycolytic characteristics of hepatocellular carcinoma and its interaction with the microenvironment: a comprehensive omics study
Dan Chen, Dandan Lin, Huling Li, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Dan Chen, Dandan Lin, Huling Li, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Engineering materials for pyroptosis induction in cancer treatment
Jiayi Liu, Taili Chen, XianLing Liu, et al.
Bioactive Materials (2023) Vol. 33, pp. 30-45
Open Access | Times Cited: 12
Jiayi Liu, Taili Chen, XianLing Liu, et al.
Bioactive Materials (2023) Vol. 33, pp. 30-45
Open Access | Times Cited: 12
Advancing Drug Discovery through Integrative Computational Models and AI Technologies
Stefano Piotto, Lucia Sessa, Eugenio Sottile, et al.
Drug repurposing (2025) Vol. 2, Iss. 1
Closed Access
Stefano Piotto, Lucia Sessa, Eugenio Sottile, et al.
Drug repurposing (2025) Vol. 2, Iss. 1
Closed Access
Targeting TIME in Advanced Hepatocellular Carcinoma: Mechanisms of Drug Resistance and Treatment Strategies
Xinyi Ye, Xizhu Fang, Fangfang Li, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104735-104735
Closed Access
Xinyi Ye, Xizhu Fang, Fangfang Li, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104735-104735
Closed Access
Pyroptosis and Its Role in the Modulation of Cancer Progression and Antitumor Immunity
Sihan Qi, Qilin Wang, Junyou Zhang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10494-10494
Open Access | Times Cited: 18
Sihan Qi, Qilin Wang, Junyou Zhang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10494-10494
Open Access | Times Cited: 18
Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma
Ying Zhu, Lun‐Xiu Qin
Hepatobiliary & pancreatic diseases international (2022) Vol. 21, Iss. 5, pp. 420-429
Closed Access | Times Cited: 16
Ying Zhu, Lun‐Xiu Qin
Hepatobiliary & pancreatic diseases international (2022) Vol. 21, Iss. 5, pp. 420-429
Closed Access | Times Cited: 16
Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report
Hongwei Sun, Chongyun Xing, Songfu Jiang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
Hongwei Sun, Chongyun Xing, Songfu Jiang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
High glucose-induced NCAPD2 upregulation promotes malignant phenotypes and regulates EMT via the Wnt/β-catenin signaling pathway in HCC
Yuhua Mai
American Journal of Cancer Research (2024) Vol. 14, Iss. 4, pp. 1685-1711
Open Access | Times Cited: 3
Yuhua Mai
American Journal of Cancer Research (2024) Vol. 14, Iss. 4, pp. 1685-1711
Open Access | Times Cited: 3
Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells
Zengbin Wang, Linqing Wu, Yu Zhou, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Zengbin Wang, Linqing Wu, Yu Zhou, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Targeting NAD+ metabolism of hepatocellular carcinoma cells by lenvatinib promotes M2 macrophages reverse polarization, suppressing the HCC progression
Qingcan Sun, Mengying Shen, Subin Zhu, et al.
Hepatology International (2023) Vol. 17, Iss. 6, pp. 1444-1460
Closed Access | Times Cited: 7
Qingcan Sun, Mengying Shen, Subin Zhu, et al.
Hepatology International (2023) Vol. 17, Iss. 6, pp. 1444-1460
Closed Access | Times Cited: 7
Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer
Huafeng Jiang, Senjun Zhou, Gang Li
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Huafeng Jiang, Senjun Zhou, Gang Li
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
The Eph/Ephrin System in Hepatocellular Carcinoma: Functional Roles and Potential Therapeutic Targets
Xin Shu, Qiang Wang, Qingming Wu
ONCOLOGIE (2022) Vol. 24, Iss. 3, pp. 427-439
Closed Access | Times Cited: 9
Xin Shu, Qiang Wang, Qingming Wu
ONCOLOGIE (2022) Vol. 24, Iss. 3, pp. 427-439
Closed Access | Times Cited: 9
